太原便血怎么引起的太原肛裂应怎样治疗,山西肛肠医院电话,太原怎么治便秘,太原切除痔疮,太原肛门周围痛痒,山西肛瘘保守治疗法,太原肛肠科检查

While millions of Americans tuned in to watch the first presidential debate between President Donald Trump and Democratic presidential nominee Joe Biden, data shows the event will likely not impact the final outcome of the election.The first of three presidential debates was held Tuesday night in Cleveland, Ohio.NewsChannel 5 Political Analyst Pat Nolan said the first debate always brings high stakes for the candidates and high interest from voters."This is probably the biggest opportunity for both candidates to get in front of voters and convince them they are the right person," said Nolan.While people tuned in to hear what both candidates had to say, Nolan said polls show the debate ultimately won't sway voters."I think people have decided, I like Donald Trump and I will vote for him, or I like Joe Biden, I will vote for Joe Biden and they won’t change their minds," said Nolan.The debate was held in Ohio, which is considered a swing state. Nolan said while the number of undecided voters may be smaller in the current polarizing political climate, winning those votes matters and can make a difference in swing states.While both President Trump and Biden presented their plans for the country and tried to energize supporters, Nolan said many were watching for a viral moment that could make or break either candidate."It's like any big event, when you are up on the stage and the bright lights are out there, anyone can make a mistake."There are still two more debates coming up in October. The second presidential debate will be Oct. 15 in Miami, and the final debate will be Oct. 22 at Belmont University in Nashville.This story was first reported by Emily Luxen at WTVF in Nashville, Tennessee. 1722

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

When is Slow Joe Biden going to criticize the Anarchists, Thugs & Agitators in ANTIFA? When is he going to suggest bringing up the National Guard in BADLY RUN & Crime Infested Democrat Cities & States? Remember, he can’t lose the Crazy Bernie Super Liberal vote!— Donald J. Trump (@realDonaldTrump) August 31, 2020 334

Whether you call it Vote by Mail or Absentee Voting, in Florida the election system is Safe and Secure, Tried and True. Florida’s Voting system has been cleaned up (we defeated Democrats attempts at change), so in Florida I encourage all to request a Ballot & Vote by Mail! #MAGA— Donald J. Trump (@realDonaldTrump) August 4, 2020 342

With just over a month until the election, Florida and Arizona are emerging as battleground states that are neck-and-neck for President Donald Trump and former vice president Joe Biden.For the first time in 2020, Trump has a slight lead in Florida, according to the Washington Post-ABC News poll. Among participants who said they are likely voters, Trump leads 51-to-47 percent, however this is considered within the margin of error.The poll points out Biden has a 13-point lead among Hispanic registered voters in Florida; four years ago, Hillary Clinton had a 27-point lead among Hispanics and still lost the state.In Arizona, among likely voters, the poll shows Trump and Biden at 49-to-48 percent. Arizona has voted for the Republican presidential candidate for every election since 1952 except once, the re-election of Bill Clinton in 1996.Researchers of this poll note that these percentages are so close the difference is not statistically significant. The margin of sampling error is 4 points among Florida results and 4.5 points among Arizona results.Trump won Florida and Arizona in the last election. In Arizona, Trump won in 2016 by about 90,000 votes. In Florida, Trump won by just over 100,000 votes.When it comes to the issues, Trump gets credit for being trusted to handle the economy, despite the current pandemic-fueled recession. In Florida, registered voters in the survey said they trusted Trump with the economy over Biden 52-to-41 percent. In Arizona, the spread is higher, with registered voters preferring Trump 56-to-41 percent.The economy appears to be the top issue for many this election cycle. About 31 percent of registered voters in Florida said the economy is the single most important issue, and 33 percent of those in Arizona.In handling the coronavirus pandemic, more registered voters trust Biden over Trump, with 48-to-43 percent in Florida and 49-to-45 percent in Arizona. In both states, 57 percent of participants said they were worried about catching the coronavirus.Biden also leads in handling health care, crime and safety, discouraging violence at political protests, and equal treatment of racial groups.Trump’s overall approval rating among registered voters is 47 percent in both states.There is also a big split in how voters of different parties plan to vote on Election Day. In both Florida and Arizona, more than 70 percent of registered Republicans plan on voting in-person on Election Day. Democratic participants are more likely to vote early or absentee/mail-in, more than 60 percent.This latest poll was conducted by landline and cell phone interviews between September 15-20 among 765 registered Florida voters and 701 registered Arizona voters. 2712